|
Match
|
Document |
Document Title |
|
|
8173781 |
Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell...
|
|
|
8153125 |
CD20 binding molecules
The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a...
|
|
|
8147832 |
CD20-binding polypeptide compositions and methods
A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be...
|
|
|
8129129 |
Method for diagnosing tumors
The present invention describes a method for diagnosing tumors of the reproductive organs which is characterized by determination of the afamin content in a sample of a body fluid or in a tissue...
|
|
|
8124738 |
Human monoclonal antibodies to CD70
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the...
|
|
|
8110195 |
Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody
The present invention relates to a cell for the production of an antibody molecule such as an antibody binding to ganglioside GM2, a fragment of the antibody and a fusion protein having the Fc...
|
|
|
8101185 |
Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation
The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion...
|
|
|
8101720 |
Immunoglobulin insertions, deletions and substitutions
An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc ...
|
|
|
8101179 |
Anti-CD20 monoclonal antibody
A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in...
|
|
|
8088378 |
Anti-CD79B antibodies and immunoconjugates and methods of use
The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those...
|
|
|
8088357 |
Tumor-specific recognition molecules
The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
|
|
|
8088896 |
Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods for using the same. These antibodies as well as the novel methods for using those...
|
|
|
8071323 |
Human monoclonal antibodies that bind human insulin like growth factors and their use
Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.
|
|
|
8067001 |
Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid...
|
|
|
8062887 |
Monoclonal antibody specifically recognizing modification site after translation of p53 and kit for assaying modification site containing the same
The present invention provides a monoclonal antibody recognizing modification after translation of p53 in a manner specific to a modification site, an antibody microarray comprising the antibody...
|
|
|
8058406 |
Composition comprising antibodies to LINGO or fragments thereof
Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such...
|
|
|
8053563 |
YKL-40 monoclonal authority
The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or...
|
|
|
8013128 |
Antibodies and related molecules that bind to PSCA proteins
Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is...
|
|
|
7994287 |
Antibodies which bind human CXCR3
Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or...
|
|
|
7977462 |
Tyrosine phosphorylation sites
The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies...
|
|
|
7973138 |
Antibodies
The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting a...
|
|
|
7968688 |
Antibodies that bind to the C35 polypeptide
The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human...
|
|
|
7968687 |
CD19 binding agents and uses thereof
This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.
|
|
|
7947812 |
Neoplasm specific antibodies and uses thereof
The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.
|
|
|
7932055 |
Soluble heterodimeric CD94/NKG2 receptors fusion proteins
Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each...
|
|
|
7919314 |
Process for the production of monoclonal antibodies
Provided is a use of a recombinant chimaeric protein as an immunogen in a process for producing a monoclonal antibody, wherein the recombinant chimaeric protein is assembled into a virus-like...
|
|
|
7897139 |
PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the...
|
|
|
7892554 |
Internalizing ErbB2 antibodies
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the...
|
|
|
7892547 |
Methods and compositions for administering therapeutic and diagnostic agents
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
|
|
|
7888485 |
Anti-pleiotrophin antibodies and methods of use thereof
The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The...
|
|
|
7887808 |
Human Rgr oncogene and truncated transcripts thereof detected in T cell malignancies, antibodies to the encoded polypeptides and methods of use
Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the...
|
|
|
7883702 |
Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies
The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and...
|
|
|
7879984 |
Human antibodies to human CD20 and method of using thereof
A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing...
|
|
|
7879990 |
Polynucleotides encoding antibodies that bind to the C35 polypeptide
The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human...
|
|
|
7872104 |
Antibody, immunoassay and method for prostate cancer detection
This invention concerns an antibody which binds with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA)....
|
|
|
7871762 |
Hyperglycosylated hCG (invasive trophoblast antigen) in differential diagnosis of malignant or invasive trophoblastic disease
The invention provides methods for detecting the presence or absence of invasive trophoblast cells. In addition, the invention provides methods for distinguishing quiescent trophoblast diseases...
|
|
|
7867725 |
Monoclonal antibodies against osteopontin
The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present...
|
|
|
7862817 |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
|
|
|
7858760 |
Antibodies to protein expressed in prostate cancer
A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on...
|
|
|
7850966 |
Method of treating breast cancer using anti-HER2 antibody variants
The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.
|
|
|
7834155 |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and...
|
|
|
7833528 |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific...
|
|
|
7820164 |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers,...
|
|
|
7812133 |
Anti-OX40L antibodies and methods using same
The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.
|
|
|
7799900 |
Immunoglobulin variants and uses thereof
The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
|
|
|
7790165 |
Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid...
|
|
|
7786266 |
Methods for damaging cells using effector function of anti-DSC2 antibody
The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate,...
|
|
|
7785812 |
Multidrug resistance-associated polypeptide
Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from...
|
|
|
7777010 |
Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
The invention provides a method for selecting at least one member from a library of proteinaceous molecules by providing at least one cell and/or a functional equivalent thereof, with at least part...
|
|
|
7776330 |
Humanized anti-CEA T84.66 antibody and uses thereof
Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes...
|